Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
    • Sale
Login
  • Donate
0

Press Releases

MAPS and MAPS PBC Publish Patient Bill of Rights for Psychedelic Therapy

Patient Bills of Rights are made available to patients in various settings across the mental health and medical fields to communicate clearly with patients about what they can expect from professionals …
February 10, 2022

MAPS PBC Adopts Charter for Independent Ethics Review Board

FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review …
February 2, 2022

MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
January 25, 2022

Awakn Life Sciences and MAPS to Explore Partnership for Treatment of Alcohol Use Disorder in Europe

FOR IMMEDIATE RELEASE On January 19, 2022, the Multidisciplinary Association for Psychedelic Studies (MAPS) and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) entered …
January 19, 2022

Science Names MDMA-Assisted Therapy for PTSD a 2021 Scientific Breakthrough of the Year

A blockbuster year of advancements in psychedelic-assisted therapies is culminating with recognition of the profound potential of emerging treatments for difficult-to-treat mental health conditions. On …
December 20, 2021

Psyche Unbound, a collection of essays in honor of Stanislav Grof, to be released in January 2022

Psyche Unbound: Essays in Honor of Stanislav Grof is an extraordinary compilation of twenty-two essays that honor the path-breaking lifework of Stanislav Grof, M.D., Ph.D., the world’s leading researcher …
December 8, 2021

MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million

Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
December 2, 2021

MAPS Announces Appointment of Carl L. Hart, Ph.D., to the Board of Directors

MAPS is honored to announce the election of Carl L. Hart, Ph.D., to MAPS’ Board of Directors, effective as of October 22, 2021. to MAPS’ Board of Directors, effective as of October 22, 2021. Dr. Carl …
November 3, 2021

Matters Arising: MAPS’ Pivotal Phase 3 Trial Advances Scientific Discourse in Nature Medicine

The results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD have sparked scientific discourse: Highly statistically significant results and exceptional outcomes for people living …
October 14, 2021

MAPS to Receive $1.5 Million to Evaluate Collaboration with Wesana Health in TBI Treatment

MAPS and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) have entered into a Memorandum of Understanding with Wesana Health Inc, a publicly traded, data-driven life …
September 14, 2021

MAPS Awarded $12.9 Million Grant from Michigan to Expand Cannabis Research for Veterans with PTSD

MAPS) has been awarded a $12,979,050 grant from Michigan’s $20 million competitive 2021 Veteran Marijuana Research Grant Program. The program, which is funded by adult-use marijuana retail taxes, is …
August 10, 2021

U.S. House Appropriations Bill Signals Sea Change in Psychedelic, Cannabis Research

The bill directs National Institute of Health (NIH) agencies to undertake and fund research into psychedelic-assisted therapies and potential benefits of cannabis, could accelerate the pace of research. …
July 30, 2021

Posts navigation

Newer Posts Page 1 … Page 3 … Page 10 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up

  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Proudly powered by WordPress. Hosted by Pressable.